| Halaven (eribulin mesylate) / Eisai |
2020-001938-35: AIRE: Investigation of the immune response after chemotherapy treatment with Eribulin: A trial for female patients with advanced breast cancer. AIRE: Untersuchung der Immunantwort nach Behandlung mit der Chemotherapie Eribulin: Eine Studie für Patientinnen mit fortgeschrittenem Brustkrebs. |
|
|
| Not yet recruiting | 4 | 84 | Europe | Eribulin, Paclitaxel, Paclitaxel Albumin-Bound, Capecitabine, Vinorelbine, Solution for injection, Concentrate for solution for infusion, Powder for solution for infusion, Tablet, Halaven, Paclitaxel, nab-Paclitaxel, Capecitabine, Vinorelbine | Institut für Frauengesundheit GmbH, Institut für Frauengesundheit (IFG) GmbH | Female patients diagnosed with HER2 negative advanced breast cancer, which had received at least one previous chemotherapy Patientinnen, die mit einem HER2 negativen Brustkrebs im fortgeschrittenem Stadium diagnostiziert wurden und zuvor mindestens eine Chemotherapie erhielten., Female patients which were diagnosed with advanced breast cancer. The tumor should not have a certain marker (HER2) on its surface (HER2 negative breast cancer). Patientinnen, die mit einem Brustkrebs im fortgeschrittenem Stadium diagnostiziert wurden. Den Tumorzellen fehlt ein bestimmter Marker (HER2) auf der Oberfläche (HER2-negativer Brustkrebs)., Diseases [C] - Cancer [C04] | | | | |
ChiCTR2000038832: A multicenter, exploratory study of Eribulin combined with Pyrotinib in patients with advanced HER2-positive breast cancer who have previously used Taxanes and are resistant to Herceptin |
|
|
| Recruiting | 4 | 50 | | Eribulin combine Pyrotinib | The Fourth Hospital of Hebei Medical University; The Fourth Hospital of Hebei Medical University, Self-funded | Breast cancer | | | | |
ChiCTR2100048468: A real-world study of the efficacy and safety of Eribulin in different subtypes of advanced breast cancer |
|
|
| Recruiting | 4 | 150 | | Eribulin | Shandong Cancer Hospital; Shandong Cancer Hospital, self-raised | breast cancer | | | | |
ChiCTR2100051610: Single-center clinical study of the effectiveness and completeness of eribulin in combination with small molecule complexine kinase inhibitors for advanced solid tumors |
|
|
| Not yet recruiting | 4 | 40 | | Chemotherapy + Targeted | Shanghai Sixth People's Hospital; Shanghai Sixth People's Hospital, Wu Jieping Medical Foundation (Clinical Research Special Grant Fund) | Tumor patients | | | | |
AIRE, NCT05033769: Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer |
|
|
| Recruiting | 4 | 82 | Europe | Eribulin Injection [Halaven], Eribulin, Paclitaxel injection, Paclitaxel | Institut fuer Frauengesundheit, Eisai GmbH | Breast Cancer Female, Neoplasm, Breast, Breast Cancer Metastatic | 07/23 | 09/23 | | |
ChiCTR2100052828: Multicenter, randomized study of eribulin plus capecitabine versus capecitabine in HER2-negative patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes |
|
|
| Recruiting | 4 | 320 | | Eribulin mesilate 1.4 mg/m^2 intravenously over 2-5 minutes on days 1 and 8 of every 21-day cycle, in combine with Capecitabine tablet 1000 mg/m^2 orally bid for days 1 to 14 of every 21-day cycle ;Capecitabine tablet 1250 mg/m^2 orally bid for days 1 to 14 of every 21-day cycle | Cancer Hospital Chinese Academy of Medical Sciences; Cancer Hospital Chinese Academy of Medical Sciences, Eisai China lnc. | Breast cancer | | | | |
ACTRN12607000176460: A Phase III Open Label, Randomized Two-Parallel-Arm Multicenter Study of E7389 versus Capecitabine in Patients with Locally Advanced or Metastatic Breast Cancer Previously Treated with Anthracyclines and Taxanes |
|
|
| Recruiting | 3 | 1100 | | | Eisai, Eisai | Breast Cancer Locally Advanced or Metastatic | | | | |
ACTRN12612000100897: Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer |
|
|
| Active, not recruiting | 3 | 540 | | | Eisai Limited, Eisai Limited | Non-small cell lung cancer | | | | |
OlympiAD, NCT02000622 / 2013-005137-20: Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. |
|
|
| Active, not recruiting | 3 | 302 | Europe, Japan, US, RoW | Olaparib, Physician's choice chemotherapy | AstraZeneca, Myriad Genetic Laboratories, Inc., Merck Sharp & Dohme LLC | Breast Cancer Metastatic, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation | 12/16 | 12/24 | | |
|
|
| Completed | 3 | 437 | Europe, Canada, US, RoW | (vic-)trastuzumab duocarmazine, SYD985, Trastuzumab vc-seco-DUBA, Physician's choice, Lapatinib (Lap), Capecitabine (Cap), Trastuzumab (T), Vinorelbine (Vino), Eribulin (Eri) | Byondis B.V. | Metastatic Breast Cancer | 03/21 | 06/22 | | |
2018-004211-42: A clinical study to compare treatment of Balixafortide in combination with Eribulin or Eribulin alone, in patients with no protein HER2 present in their cells and had locally repeated or spread breast cancer. |
|
|
| Not yet recruiting | 3 | 384 | RoW, Europe | Balixafortide, Halaven, POL6326, Concentrate for solution for infusion, Solution for injection, Halaven | Polyphor Ltd., Polyphor Ltd. | Patients with HER2 negative, Locally Recurrent or Metastatic Breast Cancer, Patients with breast cells that do not have on their surface the HER2 protein (receptor for the Human epidermal growth factor receptor 2) and that have locally repeated or spread breast cancer, Diseases [C] - Cancer [C04] | | | | |
| Terminated | 3 | 432 | Europe, US, RoW | Eribulin, Eribulin Injection [Halaven], Balixafortide, POL6326 | Spexis AG | Metastatic Breast Cancer, Locally Recurrent Breast Cancer | 10/21 | 10/21 | | |
2020-005620-12: A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Inoperable or Metastatic Hormone Receptor-positive, HER2-negative Breast Cancer Ensayo clínico de Dato-DXd en comparación con la quimioterapia de elección del investigador en cáncer de mama inoperable o metastásico, con receptores hormonales positivos HER2 negativo. |
|
|
| Not yet recruiting | 3 | 700 | Europe | Datopotamab deruxtecan, Eribulin mesylate, Capecitabine, Gemcitabine, Vinorelbine, DS-1062a, Powder for concentrate for solution for infusion, Solution for injection/infusion, Film-coated tablet, Powder for solution for infusion, HALAVEN, Capecitabine Accord, Bendacitabin, Bendarelbin | AstraZeneca AB, ASTRAZENECA AB, AstraZeneca AB | Inoperable or Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer that Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy Cáncer de mama inoperable o metastásico, con receptores hormonales positivos, HER2 negativo, tratado una o dos líneas previas de quimioterapia sistémica, Breast Cancer Cáncer de mama, Diseases [C] - Cancer [C04] | | | | |
| Active, not recruiting | 3 | 557 | Europe, Canada, Japan, US, RoW | Trastuzumab deruxtecan (DS-8201a), DS-8201a, Capecitabine, Eribulin, Gemcitabine, Paclitaxel, Nab-paclitaxel | Daiichi Sankyo, Daiichi Sankyo Co., Ltd., AstraZeneca | Breast Cancer | 01/22 | 10/25 | | |
|
|
|
|
EMERALD, NCT03264547: A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab |
|
|
| Recruiting | 3 | 480 | Japan | Pertuzumab, Perjeta, Trastuzumab, Herceptin, Docetaxel, Taxotere, Paclitaxel, Taxol, Eribulin, Halaven | Japan Breast Cancer Research Group, Eisai Co., Ltd. | Breast Cancer | 04/22 | 10/23 | | |
| Active, not recruiting | 3 | 331 | RoW | Sacituzumab Govitecan-hziy, IMMU-132, Trodelvy™, GS-0132, Eribulin Mesylate Injection, Halaven, Capecitabine Oral Product, Xeloda, Gemcitabine Injection, Gemzar, Vinorelbine injection, Navelbine | Gilead Sciences, Iqvia Pty Ltd, Medidata Solutions, Parexel | Metastatic Breast Cancer | 12/25 | 12/25 | | |
NCT05134194: A Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy Regimen for Metastatic Triple-negative Breast Cancer |
|
|
| Terminated | 3 | 1 | RoW | Camrelizumab、Capecitabine/eribulin/gemcitabine/vinorelbine, Capecitabine/eribulin/gemcitabine/vinorelbine | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Triple Negative Breast Cancer | 01/22 | 12/22 | | |
NCT06143553: Paclitaxel Polymeric Micelles for Injection Versus TPC on the Treatment of HER2-negative Metastatic Breast Cancer (MBC). |
|
|
| Recruiting | 3 | 168 | RoW | Paclitaxel Polymeric Micelles for Injection, Eribulin Mesilate injection, Capecitabine Tablets, Gemcitabine Hydrochloride for Injection, Vinorelbine Tartrate Injection, Paclitaxel (albumin-bound) | Shanghai Yizhong Pharmaceutical Co., Ltd. | Metastatic Breast Cancer (MBC) | 07/25 | 07/25 | | |
NCT05346861: Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab |
|
|
| Recruiting | 3 | 240 | RoW | Trastuzumab plus chemotherapy, Trastuzumab in combination with pyrotinib plus chemotherapy | Fudan University | HER2-positive Breast Cancer, Metastatic Breast Cancer | 10/23 | 10/24 | | |
OptiTROP-Breast01, NCT05347134: SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer |
|
|
| Active, not recruiting | 3 | 254 | RoW | SKB264, Eribulin, Capecitabine, Gemcitabine, Vinorelbine | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Triple Negative Breast Cancer | 10/23 | 12/24 | | |
B2023-686-01, NCT06268652: Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer |
|
|
| Recruiting | 3 | 302 | RoW | Organoid-guided personalized treatment, OGPT, Gemcitabine, Gemzar, Capecitabine, Xeloda, Vinorelbine, Navelbine, Eribulin, Halaven | Sun Yat-sen University | Breast Cancer, Refractory Breast Carcinoma | 02/26 | 01/28 | | |
SYSKY-2023-1016-01, NCT06255392: Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer |
|
|
| Not yet recruiting | 3 | 200 | RoW | Fluzoparib, Apatinib Mesylate, Capecitabine tablets, Vinorelbine Tartrate Oral, Eribulin mesylate injection, Gemcitabine Hydrochloride, Paclitaxel-albumin | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Breast Cancer | 03/31 | 03/31 | | |
SKB264-Ⅲ-11, NCT06279364: A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer |
|
|
| Not yet recruiting | 3 | 524 | RoW | SKB264, Paclitaxel, Nab-paclitaxel, Capecitabine, Eribulin, Carboplatin | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Triple Negative Breast Cancer | 07/26 | 07/26 | | |
NCT06343948: A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer |
|
|
| Recruiting | 3 | 382 | RoW | BL-B01D1, Eribulin, Vinorelbine, Gemcitabine, Capecitabine | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | HR+HER2- Breast Cancer | 05/26 | 05/26 | | |
NCT06382142: A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer |
|
|
| Not yet recruiting | 3 | 436 | RoW | BL-B01D1, Eribulin, Vinorelbine, Gemcitabine, Capecitabine | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Triple-Negative Breast Cancer | 05/26 | 05/26 | | |
INVINCIBLE-3, NCT06263231: A Study to Investigate Efficacy & Safety of INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas |
|
|
| Recruiting | 3 | 333 | US | INT230-6, Eribulin, Trabectedin, Pazopanib | Intensity Therapeutics, Inc., Premier Research Group plc | Sarcoma,Soft Tissue | 12/27 | 12/28 | | |
NCT06383767: A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer |
|
|
| Not yet recruiting | 3 | 378 | RoW | ESG401, Eribulin, capecitabine, gemcitabine or vinorelbine (Treatment of Physician's Choice) | Shanghai Escugen Biotechnology Co., Ltd | Metastatic Breast Cancer | 07/26 | 12/26 | | |
JZP598-303, NCT06435429: A Phase 3, Randomized, Open-label, Controlled Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer |
|
|
| Not yet recruiting | 3 | 550 | NA | Zanidatamab, Trastuzumab, Eribulin, Vinorelbine, Gemcitabine, Capecitabine | Jazz Pharmaceuticals | Metastatic HER2-positive Breast Cancer | 04/31 | 04/31 | | |
| Active, not recruiting | 3 | 271 | Europe | pertuzumab, Perjeta®, Trastuzumab, Herceptin®, Capecitabine, Paclitaxel, Vinorelbine, Docetaxel, Exemestane, Letrozole, Anastrozole, Fulvestrant, Ribociclib, Kisqali®, nab-Paclitaxel, eribulin, leuprorelin, goserelin | Prof. Wolfgang Janni, Roche Pharma AG, Novartis Pharmaceuticals, Eisai GmbH, Celgene Corporation | Metastatic Breast Cancer | 01/25 | 01/25 | | |
| Completed | 3 | 543 | Europe, Canada, US | Sacituzumab Govitecan-hziy, IMMU-132, GS-0132, Eribulin, Capecitabine, Gemcitabine, Vinorelbine | Gilead Sciences | Metastatic Breast Cancer | 10/23 | 10/23 | | |
|
|
|
|
|
|
|
| Not yet recruiting | 3 | 150 | NA | ANG1005, paclitaxel trevatide, Physician's Best Choice, capecitabine, eribulin, high-dose IV methotrexate. | Angiochem Inc | Leptomeningeal Carcinomatosis, Leptomeningeal Metastases, Brain Metastases, HER2-negative Breast Cancer | 12/24 | 12/24 | | |
BCTOP-T-M02, NCT05760378: Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC. |
|
|
| Recruiting | 3 | 223 | RoW | Famitinib, Camrelizumab, nab-Palitaxel/Capecitabine/Eribulin Mesylate/Carboplatin | Fudan University | Triple-Negative Breast Cancer | 01/25 | 01/27 | | |
| Recruiting | 3 | 530 | RoW | SHR-A1811, Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel | Jiangsu HengRui Medicine Co., Ltd. | Breast Cancer | 01/25 | 06/26 | | |
JSKN003-302, NCT06079983: JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects |
|
|
| Not yet recruiting | 3 | 400 | RoW | JSKN003, Capecitabine tablets, Gemcitabine hydrochloride for injection, Vinorelbine tartrate injection, Paclitaxel for injection (albumin-bound type), Docetaxel injection, Eribulin mesylate injection | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Breast Cancer | 04/25 | 03/29 | | |
BRIA-ABC, NCT06072612: Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. |
|
|
| Recruiting | 3 | 404 | US | SV-BR-1-GM, Part of the Bria-IMT regimen, Cyclophosphamide, Interferon infiltration of the inoculation site, Retifanlimab, Treatment of Physician's Choice | BriaCell Therapeutics Corporation | Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic, End Stage Cancer | 06/25 | 12/25 | | |
BCTOP-T-M03, NCT05954442: Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype |
|
|
| Recruiting | 3 | 203 | RoW | Everolimus, Afinitor, Investigator's Choice of Chemotherapy, ICC | Fudan University | Triple Negative Breast Cancer, Metastatic Breast Cancer, Mutation | 08/25 | 08/26 | | |
TROPION-Breast01, NCT05104866 / 2020-005620-12: A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy |
|
|
| Active, not recruiting | 3 | 732 | Europe, Canada, Japan, US, RoW | Dato-DXd, Datopotamab deruxtecan (Dato-DXd, DS-1062a), Capecitabine, Gemcitabine, Eribulin, Eribulin Mesylate, Vinorelbine | AstraZeneca, Daiichi Sankyo | Breast Cancer | 08/25 | 08/25 | | |
|
|
BCTOP-T-M01, NCT05806060: Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer |
|
|
| Recruiting | 3 | 192 | RoW | VEGFR and nab-paclitaxel, with maintenance of VEGFR and capecitabine, Bevacizumab (BP102), nab-paclitaxel, with maintenance of capecitabine, Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1, VEGFR and TPC | Fudan University | Triple-Negative Breast Cancer | 08/25 | 02/26 | | |
TROPION-Breast02, NCT05374512 / 2021-005223-21: A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy |
|
|
| Recruiting | 3 | 600 | Europe, Canada, Japan, US, RoW | Dato-DXd, Datopotamab deruxtecan (Dato-DXd, DS-1062a), Paclitaxel, Nab-paclitaxel, Carboplatin, Capecitabine, Eribulin mesylate | AstraZeneca, Daiichi Sankyo | Breast Cancer | 12/25 | 12/25 | | |
|
|
| Not yet recruiting | 3 | 376 | NA | SKB264, Eribulin, Capecitabine, Gemcitabine, Vinorelbine | Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | Metastatic Breast Cancer | 03/26 | 12/27 | | |
| Active, not recruiting | 3 | 27 | Europe | Trastuzumab, Herceptin, Alpelisib, Piqray, Fulvestrant, Faslodex, Vinorelbine, Navelbine, Capecitabine, Xeloda, Eribulin, Halaven | Spanish Breast Cancer Research Group, ETOP IBCSG Partners Foundation, Breast International Group, Novartis Pharmaceuticals | Advanced Breast Cancer | 11/24 | 11/24 | | |
SWOG S1937, NCT04579224: Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer |
|
|
| Recruiting | 3 | 184 | US | Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Docetaxel, Docecad, RP 56976, RP56976, Taxotere, Taxotere Injection Concentrate, Eribulin Mesylate, B1939 Mesylate, E7389, ER-086526 Mesylate, Halaven, Halichondrin B Analog, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY-188011, LY188011, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Sacituzumab Govitecan, hRS7-SN38 Antibody Drug Conjugate, IMMU-132, RS7-SN38, Sacituzumab Govitecan-hziy, Trodelvy | National Cancer Institute (NCI) | Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma, Refractory Renal Pelvis Urothelial Carcinoma, Refractory Ureter Urothelial Carcinoma, Refractory Urethral Urothelial Carcinoma, Refractory Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis and Ureter Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Stage IVA Bladder Cancer AJCC v8, Stage IVB Bladder Cancer AJCC v8 | 08/27 | 08/27 | | |
jRCTs031190152: JCOG1802: A randomized phase II trial of 2nd line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib |
|
|
| Active, not recruiting | 2 | 120 | Japan | Yondelis (trabectedin) - Otsuka, PharmaMar, Valeo Pharma, J&J, Halaven (eribulin mesylate) - Eisai, Votrient (pazopanib) - Novartis, BeiGene | Oita University Hospital, National Cancer Center Japan,Japan Agency for Medical Research and Development | Advanced soft tissue sarcoma | | | | |
2012-003505-10: Gemcitabine and Eribulin as first line treatment of advanced triple-negative breast cancer. Gemcitabina ed Eribulina come trattamento di prima linea nel carcinoma mammario triplo-negativo in fase avanzata. |
|
|
| Ongoing | 2 | 83 | Europe | GEMCITABINA HOS.IT*INF FL 1G, HALAVEN*EV 6FL 2ML 0,44MG/ML, GEMCITABINA HOS.IT*INF FL 1G, HALAVEN*EV 6FL 2ML 0,44MG/ML | GRUPPO ONCOLOGICO ITALIANO DI RICERCA, EISAI Srl | Locally recurrent or metastatic triple negative breast cancer. Pazienti con tumore della mammella triplo negativo con recidiva locale o metastatico. | | | | |
2017-003621-15: A Phase II study of a Combination of Eribulin and capecitabiNe in second line Treatment after the failure of gemcitabine/abraxane first line in advanced pancreatic cancer Studio di Fase II di eribulina in combinazione con capecitabina per il trattamento di seconda linea in pazienti affetti da carcinoma pancreatico avanzato dopo fallimento di terapia di prima linea con gemcitabina/abraxane. |
|
|
| Not yet recruiting | 2 | 25 | Europe | HALAVEN, Capecitabina accord 150, Capecitabina Accord 500, [-], Solution for infusion, Film-coated tablet, HALAVEN - 0.44MG/ML - SOLUZIONE INIETTABILE - USO ENDOVENOSO - FLACONCINO(VETRO) 2ML 6 FLACONCINI, CAPECITABINA ACCORD - 150 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PVC/PVDC/ALU) - 120 COMPRESSE, CAPECITABINA ACCORD - 500 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PVC/PVDC/ALU) - 120 COMPRESSE | AZIENDA OSPEDALIERO-UNIVERSITARIA DI MODENA, EISAI srl | advanced pancreatic cancer tumore del pancreas avanzato, advanced pancreatic cancer tumore del pancreas avanzato, Diseases [C] - Cancer [C04] | | | | |
2017-004652-35: Second line ERIbulin followed by CApecitabine or the reverse sequence in HER2-negative Metastatic Breast Cancer (MBC) patients: a randomized phase II study – ERICA trial ERIbulina in seconda linea seguita da CApecitabina o sequenza inversa in pazienti con carcinoma mammario metastatico (MBC) HER2-negativo: uno studio randomizzato di fase II – Studio ERICA |
|
|
| Ongoing | 2 | 150 | Europe | HALAVEN, Xeloda, [Eribulina], [Capecitabina], Solution for injection, Film-coated tablet, HALAVEN - 0.44MG/ML - SOLUZIONE INIETTABILE - USO ENDOVENOSO - FLACONCINO(VETRO) 2ML 6 FLACONCINI, XELODA - 500 MG 120 COMPRESSE FILMRIVESTITE IN BLISTER USO ORALE | CONSORZIO ONCOTECH, EISAI S.r.l. | HER2-negative Metastatic Breast Cancer Carcinoma mammario metastatico HER2-negativo, Metastatic Breast Tumour Tumore al seno metastatico, Diseases [C] - Cancer [C04] | | | | |
NCT03051659: A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer |
|
|
| Completed | 2 | 90 | US | Eribulin Mesylate, Halaven, Pembrolizumab, Keytruda | Dana-Farber Cancer Institute, Merck Sharp & Dohme LLC | Breast Cancer | 10/18 | 09/23 | | |
|
2018-004571-12: Trial in advanced Solitary Fibrous Tumor (SFT) Studio clinico nel Tumore Fibroso Solitario (TFS) |
|
|
| Not yet recruiting | 2 | 20 | Europe | Eribulina, [30058], Solution for injection, HALAVEN - 0.44MG/ML - SOLUZIONE INIETTABILE - USO ENDOVENOSO - FLACONCINO(VETRO) 2ML 6 FLACONCINI | ITALIAN SARCOMA GROUP, Eisai Italy | Advanced Solitary Fibrous Tumor (SFT) Tumore Fibroso Solitario in fase avanzata, Advanced Solitary Fibrous Tumor (SFT) Tumore Fibroso Solitario in fase avanzata, Diseases [C] - Cancer [C04] | | | | |
2020-004909-32: Can treatment with Eribulin chemotherapy restore the sentivity in cancertissue in subsequent treatment with antihormon treatment? A study for patients with ER positive, HER2 normal breast cancer. Kan behandling med kemoterapien eribulin genskabe kræftvævets følsomhed for efterfølgende antihormonbehandling. Et studie til patienter med ER positiv, HER2 normal brystkræft. |
|
|
| Not yet recruiting | 2 | 42 | Europe | Halaven, Concentrate and solvent for solution for infusion, Tablet, Halaven, Aromasin | Department of Oncology, Department of oncology, University Hospital of Aarhus, Skejby | Metastatic breast cancer with estrogene positive and HER2 normal/negative subtype. Metastatisk brystkræft med østrogenreceptor positive og HER2 normal/negative HER2 receptor status., Breast cancer with has spred to other organs with is sentitive to estrogen and has a normal HER2 receptor status. Brystkræft med spredning til andre organer som er østrogen receptor positive og har HER2 normal udtryk ved immunhistokemi., Diseases [C] - Cancer [C04] | | | | |
2017-004324-30: Clinical Trial to study the effect of the treatment with eribulin and endocrine therapy in metastatic breast cancer patients Ensayo clínico para estudiar el efecto de tratamiento con eribulina y terapia endocrina en pacientes con cáncer de mama avanzado |
|
|
| Not yet recruiting | 2 | 60 | Europe | Solution for injection, HALAVEN | Medica Scientia Innovation Research (MEDSIR), EISAI FARMACEUTICA S.A. | Luminal Metastatic Breast Cancer Cáncer de mama metastásico luminal, Metastatic Breast Cancer Cáncer de mama metastásico, Diseases [C] - Cancer [C04] | | | | |
NCT02623972: A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer |
|
|
| Active, not recruiting | 2 | 22 | US | Eribulin, Halaven, B1939 mesylate, Adriamycin, Doxorubicin, Cyclophosphamide, Cytoxan®, Neosar® | Dana-Farber Cancer Institute, Eisai Inc. | Inflammatory Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | 05/21 | 12/26 | | |
NCT04624711: Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast Cancer |
|
|
| Recruiting | 2 | 40 | RoW | Eribulin Mesylate, Halaven, Anlotinib hydrochloride, Anlotinib | The First Affiliated Hospital with Nanjing Medical University | HER2-negative Breast Cancer | 06/22 | 12/22 | | |
TEMPLATE, NCT04913571: Tislelizumab in Combination With Eribulin for Patients With Metastatic Previously heaviLy-treAted TriplE-negative Breast Cancer：A Prospective Multiple-center Phase II Study |
|
|
| Not yet recruiting | 2 | 265 | RoW | Eribulin, Tislelizumab | Fudan University | Triple Negative Breast Cancer | 06/22 | 06/23 | | |
NCT03331250: Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE) |
|
|
| Active, not recruiting | 2 | 13 | US | Eribulin, Halaven | Massachusetts General Hospital, Eisai Inc. | Angiosarcoma, Epithelioid Hemangioendothelioma | 07/22 | 05/25 | | |
NCT04517292: Eribulin Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC) |
|
|
| Not yet recruiting | 2 | 160 | RoW | Eribulin,cisplatin, Gemcitabine,cisplatin | Fudan University | Breast Cancer | 07/22 | 10/22 | | |
| Active, not recruiting | 2 | 46 | RoW | Camrelizumab, Apatinib, Eribulin, Eribulin Mesylate | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Breast Cancer | 11/22 | 08/23 | | |
| Active, not recruiting | 2 | 1460 | Europe | AZD2014, AZD4547, AZD5363, AZD8931, Selumetinib, ARRY-142866, Vandetanib, CAPRELSA, Bicalutamide, Casodex, Olaparib, Lynparza, Anthracyclines, Doxorubicin, Epirubicin, liposomal doxorubicin, Taxanes, paclitaxel, docetaxel, cyclophosphamide, Novatrex, Imeth, DNA intercalators, capecitabine, 5-FU, gemcitabine, Methotrexate, vinca alkaloids, vinorelbine, vinblastine, vincristine, Platinum based chemotherapies, Platinum, carboplatin, cisplatin, Bevacizumab, Avastin, Mitomycin C, Ametycine, Eribulin, Halaven, MEDI4736 | UNICANCER, Fondation ARC, AstraZeneca | Metastatic Breast Cancer | 12/22 | 12/24 | | |
NCT05546255: Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer |
|
|
| Recruiting | 2 | 40 | RoW | Eribulin Mesylate, Lobaplatin | Chinese Academy of Medical Sciences | Triple Negative Breast Cancer | 12/22 | 12/23 | | |
NCT05402722: Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer |
|
|
| Recruiting | 2 | 30 | RoW | Eribulin, Halaven, anti-PD-1 antibody | Beijing 302 Hospital | TNBC - Triple-Negative Breast Cancer | 12/22 | 06/23 | | |
NCT04745975: Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer |
|
|
| Recruiting | 2 | 100 | RoW | Personalized treatment guided by mini-PDX and RNA sequencing, Nab paclitaxel, Eribulin, Vinorelbine, Gemcitabine, Capecitabine | Fudan University | Triple Negative Breast Cancer | 01/23 | 01/23 | | |
2022-001398-30: PHASE II STUDY WITH MEN1611 MONOTHERAPY OR IN COMBINATION WITH ERIBULIN FOR ADVANCED METAPLASTIC BREAST CANCER. ESTUDIO FASE II CON MEN1611 EN MONOTERAPIA O EN COMBINACION CON ERIBULINA EN PACIENTES CON CANCER DE MAMA METAPLÁSICO AVANZADO |
|
|
| Not yet recruiting | 2 | 28 | Europe | MEN1611, Halaven, MEN1611, Halaven, Capsule, Injection/infusion, Halaven | Medica Scientia Innovation Research, S.L., Menarini SRL | Hormone Receptor (HR)-known/ Human Epidermial Growth Factor Receptor 2 (HER2)-negative, phosphatidylinositol-4,5-bisphosphate 3kinase catalytic subunit alpha (PIK3CA)/ Phosphatase and Tensin Homolog (PTEN)-altered, unresectable locally advanced or metastatic metaplastic breast carcinoma (MpBC) Hormone Receptor (HR)-known/ Human Epidermial Growth Factor Receptor 2 (HER2)-negative, phosphatidylinositol-4,5-bisphosphate 3kinase catalytic subunit alpha (PIK3CA)/ Phosphatase and Tensin Homolog (PTEN)-altered, unresectable locally advanced or metastatic metaplastic breast carcinoma (MpBC) , Advanced or metastatic metaplastic breast cancer Cancer de mama metaplasico avanzado, Diseases [C] - Cancer [C04] | | | | |
EMBRAVE-001, NCT04502680: Maintenance Treatment With Eribulin Mesylate Versus Observation in Triple Negative Breast Cancer Patients |
|
|
| Not yet recruiting | 2 | 100 | RoW | Eribulin Mesylate, Halaven | The First Affiliated Hospital with Nanjing Medical University | Triple Negative Breast Cancer | 06/23 | 06/24 | | |
| Active, not recruiting | 2 | 122 | Europe | Eribulin Mesylate, Eribulin, Capecitabine | Consorzio Oncotech, EISAI S.r.l. | Metastatic Breast Cancer | 07/23 | 07/23 | | |
NCT03899805: A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas |
|
|
| Active, not recruiting | 2 | 57 | US | Eribulin, Halaven, Pembrolizumab, Keytruda | Dana-Farber Cancer Institute, Merck Sharp & Dohme LLC | Sarcoma, Liposarcoma, Leiomyosarcoma, Undifferentiated Pleomorphic Sarcoma | 08/25 | 08/25 | | |
NCT04681911: Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer |
|
|
| Recruiting | 2 | 71 | RoW | Inetetamab, Pyrotinib, Capecitabine, xeloda or other names, Gemcitabine, Gemzar or other names, Vinorelbine, Navelbine or other names, Carboplatin, Paraplatin or other names, Albumin paclitaxel, Abraxane or other names, Eribulin, Halaven | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Breast Cancer | 09/23 | 09/24 | | |
| Recruiting | 2 | 30 | US | Tucatinib, TUKYSA, Eribulin, HALAVEN, Trastuzumab, HERCEPTIN | Criterium, Inc. | Breast Cancer | 06/27 | 08/27 | | |
PATHFINDER, NCT04464174: Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer |
|
|
| Completed | 2 | 54 | Europe | Ipatasertib, GDC-0068, Capecitabine, Xeloda, Eribulin, Halaven, Carboplatin, Paraplatin, Gemcitabine, Gemzar | MedSIR, Hoffmann-La Roche | Triple Negative Breast Cancer | 11/23 | 11/23 | | |
| Completed | 2 | 73 | Europe | Palbociclib, Ibrance, Trastuzumab, Herceptin, Endocrine therapy, ET, Chemotherapy, CT, Antibody-Drug Conjugates, Trastuzumab emtansine (TDM-1) | SOLTI Breast Cancer Research Group | Metastatic Breast Cancer | 09/23 | 11/23 | | |
ZDWY.XBZL.002, NCT05263882: Gemcitabine Combined With Eribulin Regimen in the Treatment of Second-line Above Recurrent HER2-negative Breast Cancer |
|
|
| Not yet recruiting | 2 | 58 | NA | Gemcitabine combined with eribulin | Fifth Affiliated Hospital, Sun Yat-Sen University | HER2-negative Breast Cancer | 12/23 | 09/24 | | |
NCT03237780: Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer |
|
|
| Active, not recruiting | 2 | 72 | US | Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography with Contrast, Contrast Enhanced Computed Tomography, CONTRAST ENHANCED CT SCAN, Contrast-enhanced Computed Tomography, CT Scan With Contrast, CT with Contrast, Eribulin Mesylate, B1939 Mesylate, E7389, ER-086526 Mesylate, Halaven, Halichondrin B Analog | National Cancer Institute (NCI) | Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma, Recurrent Ureter Urothelial Carcinoma, Recurrent Urethral Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Unresectable Bladder Urothelial Carcinoma, Unresectable Renal Pelvis Urothelial Carcinoma, Unresectable Ureter Urothelial Carcinoma, Unresectable Urethral Urothelial Carcinoma | 06/25 | 06/25 | | |
NCT06202313: Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer |
|
|
| Not yet recruiting | 2 | 128 | RoW | Cadonilimab, AK104, Eribulin | Shengjing Hospital | Triple Negative Breast Cancer | 12/25 | 12/28 | | |
NCT05945368: A Trial of Eribulin in Combination With HP Neoadjuvant Therapy in Patients With for HER2-Positive BC |
|
|
| Recruiting | 2 | 78 | RoW | Eribulin mesylate injection、Pertuzumab、Trastuzumab, Eribulin+HP | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | HER2-positive Breast Cancer | 02/24 | 02/25 | | |
ESPERO, NCT05530057: Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer |
|
|
| Recruiting | 2 | 180 | RoW | Eribulin Mesylate + Samfenet (Trastruzumab-biosimilar), Eribulin Mesylate | Seoul National University Hospital | Advanced Breast Cancer | 02/24 | 12/25 | | |
NCT06308939: Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial |
|
|
| Not yet recruiting | 2 | 81 | RoW | Eribulin, eribulin mesylate, Sintilimab | Zhejiang Cancer Hospital | Metastatic Breast Cancer | 12/25 | 08/26 | | |
ChiCTR2200059629: Eribulin plus anlotinib for the treatment of refractory and advanced soft tissue sarcoma after failure of standard therapy：a prospective, open-label, single arm and single center clinical study |
|
|
| Recruiting | 2 | 30 | | Eribulin plus anlotinib | Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences; Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, partly self-funded，partly provied by Eisai China Inc. | Soft tissue Sarcoma | | | | |
| Recruiting | 2 | 16 | Europe | Eribulin, Intervention under investigation | Italian Sarcoma Group, Eisai Inc. | Solitary Fibrous Tumor | 04/24 | 04/24 | | |
NCT06355024: Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer |
|
|
| Not yet recruiting | 2 | 10 | NA | Inosine, Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum | Fudan University | Triple-negative Breast Cancer | 12/24 | 01/25 | | |
NCT06355037: Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer |
|
|
| Not yet recruiting | 2 | 10 | NA | Quercetin, Dasatinib, Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum | Fudan University | Triple-negative Breast Cancer | 12/24 | 01/25 | | |
| Recruiting | 2 | 120 | US | Paxman Scalp Cooling System, Scalp Cooling Cap, Eribulin, Halaven, Sacituzumab govitecan, Trodelvy, IMMU-132, Trastuzumab deruxtecan, Enhertu, DS-8201a | Dana-Farber Cancer Institute, Paxman Coolers Limited, AstraZeneca, Eisai Inc., Daiichi Sankyo, Gilead Sciences | Metastatic Breast Cancer, Chemotherapy-induced Alopecia | 06/26 | 06/28 | | |
NCT06387628: LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer |
|
|
| Recruiting | 2 | 74 | RoW | LM-108, Toripalimab, Eribulin, Nab paclitaxel | Fudan University | TNBC - Triple-Negative Breast Cancer | 04/26 | 04/27 | | |
NCT02035813: DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs). |
|
|
| Completed | 2 | 116 | Europe | Ribociclib, Kisqali, Eribulin, Halaven | Prof. Wolfgang Janni | HER2-negative and Hormone-receptor Positive Metastatic Breast Cancer, HER2-negative Circulating Tumor Cells, Postmenopausal Female Patients | 01/24 | 01/24 | | |
| Recruiting | 2 | 30 | Europe, Canada, RoW | Eribulin Mesylate, Halaven, Pembrolizumab, Keytruda | Australia New Zealand Gynaecological Oncology Group, Eisai Inc., Merck Sharp & Dohme LLC | Ovarian Carcinosarcoma, Uterine Carcinosarcoma | 12/24 | 12/26 | | |
NCT05621434: A Study to Evaluate Inetetamab + Pyrotinib + Chemotherapy in Previously Untreated HER2-Positive Metastatic Breast Cancer |
|
|
| Not yet recruiting | 2 | 63 | NA | Inetetamab, pyrotinib, chemotherapy, Inetetamab for injection, Pyrotinib maleate | Fujian Medical University | HER2-positive Recurrent/Metastatic Breast Cancer | 12/24 | 12/25 | | |
NCT03202316: Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer |
|
|
| Active, not recruiting | 2 | 35 | US | Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Cobimetinib, Cotellic, GDC-0973, MEK Inhibitor GDC-0973, XL518, Eribulin, ER-086526, Laboratory Biomarker Analysis, Pharmacological Study | M.D. Anderson Cancer Center | Recurrent Breast Inflammatory Carcinoma, Stage IV Breast Inflammatory Carcinoma | 12/24 | 12/24 | | |
NCT05420779: A Study to Evaluate the Efficacy and Safety of TSL-1502 Capsules in Breast Cancer Patients With Germline BRCA Mutations |
|
|
| Recruiting | 2 | 125 | RoW | TSL-1502 capsules(low dose), TSL-1502 capsules(high dose), Investigator's choice of chemotherapy | Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. | Breast Cancer Metastatic | 12/24 | 06/26 | | |
ChiCTR2300072293: An exploratory study on the first-line treatment of advanced unresectable soft tissue sarcoma with zimberelimab administered in combination with anlotinib and eribulin |
|
|
| Recruiting | 2 | 30 | | zimberelimab administered in combination with anlotinib and eribulin | Sanhuan Cancer Hospital, Chaoyang District, Beijing; Sanhuan Cancer Hospital, selt-funded | soft tissue sarcoma | | | | |
SABINA, NCT05810870: PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin |
|
|
| Recruiting | 2 | 28 | Europe | MEN1611, Eribulin, HALAVEN, Eribulin mesylate | MedSIR, Menarini Group | Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer | 07/25 | 07/27 | | |
ChiCTR2300067650: Safety and efficacy of eribulin combined with anlotinib followed by anlotinib maintenance in advanced soft tissue sarcoma patients with intolerance or failure of doxorubicin-based chemotherapy: a prospective single-arm phase II study |
|
|
| Not yet recruiting | 2 | 30 | | Treatment with eribulin and anlotinib | West China Hospital, Sichuan University; West China Hospital, Sichuan University, No | Soft-Tissue Sarcoma | | | | |
TEASTS, ChiCTR2300071221: Efficacy of Tislelizumab administered in combination with eribulin and anlotinib for patients (pts) with advanced adult soft tissue sarcoma |
|
|
| Recruiting | 2 | 26 | China | Tislelizumab + iribrin + arotinib | Zhongshan Hospital, Fudan University ; Zhongshan Hospital, Fudan University, Zhongguancun Foundation | soft tissue sarcoma (STS) | | | | |
NCT05826964: Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer |
|
|
| Recruiting | 2 | 500 | US | AI+CDK4/6i, Aromatase Inhibitor (AI) + Cyclin dependent kinase 4 and 6 inhibitor (CDK4/6i), Anastrozole, Letrozole, Exemestane, Palbociclib, Ribociclib, Abemaciclib, SERD+CDK4/6i, Selective Estrogen Receptor Degrader (SERD) + CDK4/6i, Fulvestrant, mTOR inhibitor + AI, Mammalian target of rapamycin (mTOR) inhibitor + Aromatase Inhibitor (AI), Everolimus, mTOR inhibitor + SERD, mTOR inhibitor + Selective estrogen receptor modulator, Tamoxifen, PI3K inhibitor + SERD, Phosphoinositide 3-kinase (PI3K) inhibitor + SERD, Alpelisib, PI3K inhibitor + AI, Chemotherapy, Taxane, Eribulin, Capecitabine, Vinorelbine, Oral SERD, Elacestrant | University of Miami | Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer | 07/26 | 07/29 | | |
| Recruiting | 2 | 252 | RoW | Organoid-guided treatment, Taxane, Abraxane, Lipusu, Capecitabine, Xeloda, Gemcitabine, Gemzar, Vinorelbine, Navelbine, Eribulin, Halaven, Anthracycline, Doxil, Lipodox, Carboplatin, Paraplatin, Utidelone, UTD1, Trastuzumab deruxtecan, Enhertu, Sacituzumab govitecan, Trodelvy | Guangdong Provincial People's Hospital, First Affiliated Hospital, Sun Yat-Sen University, Sun Yat-sen University, Shantou Central Hospital | HER2-negative Breast Cancer, Advanced Breast Cancer | 06/27 | 06/28 | | |
| Recruiting | 2 | 55 | US | Eribulin, SDX-7320, Placebo | Memorial Sloan Kettering Cancer Center, SynDevRx, Inc. | Breast Cancer, Metastatic Triple-Negative Breast Cancer | 10/27 | 10/27 | | |
TBCRC 058, NCT06099769: A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer |
|
|
| Recruiting | 2 | 201 | US | Enzalutamide, Mifepristone, TPC | Memorial Sloan Kettering Cancer Center, Astellas Pharma US, Inc., Breast Cancer Research Foundation, Corcept Therapeutics | Metastatic Breast Cancer | 10/27 | 10/27 | | |
2019-000998-23: Study that tested S64315 plus different standard treatments in patients with breast cancer Estudio de Fase I/II de S64315 en combinación con varios tratamientos estándar incluyendo terapia hormonal y agentes citotóxicos en cáncer de mama (CM) localmente avanzado o metastásico |
|
|
| Ongoing | 1/2 | 290 | Europe | S64315, S64315 (also referred as MIK665), Concentrate for solution for infusion, Solution for injection, Halaven, Falsodex, Paclitaxel 6mg/mL | Institut de Recherches Internationales Servier, Laboratorios Servier S.L. (Promotor Local) | Locally advanced or metastatic breast cancer. Cáncer de mama metastásico o localmente avanzado, Breast cancer that has come back and spread to the tissues and lymph nodes around the chest, neck and under the breastbone, or that has spread to other parts of the body beyond the original tumor Cáncer de mama que ha progresado y se ha propagado a los tejidos y ganglios linfáticos alrededor del tórax, el cuello y debajo del esternón, o que se ha diseminado a otras partes del cuerpo, Diseases [C] - Cancer [C04] | | | | |
| Active, not recruiting | 1/2 | 30 | RoW | Eribulin, Halaven, Lenvatinib, Lenvima | National Taiwan University Hospital, Taipei Veterans General Hospital, Taiwan | Leiomyosarcoma, Liposarcoma, Soft Tissue Sarcoma Adult, Advanced Cancer | 06/21 | 06/23 | | |
POLTER, NCT04826016: POL6326 (Balixafortide) Plus Nab-paclitaxel or Eribulin in Patients With HER2-negative Advanced Breast Cancer |
|
|
| Withdrawn | 1/2 | 168 | NA | POL6326, Balixafortide, Eribulin, Halaven, Nab paclitaxel, Abraxane | MedSIR | Advanced Breast Cancer | 03/22 | 03/22 | | |
| Active, not recruiting | 1/2 | 90 | RoW | Nivolumab, Opdivo | Seoul National University Hospital, Seoul National University Bundang Hospital, Korean Cancer Study Group (KCSG), Eisai Korea Inc., Ono pharmaceutical Korea | Metastatic Breast Cancer | 04/22 | 12/22 | | |
NCT06202261: A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer |
|
|
| Recruiting | 1/2 | 154 | RoW | TQB2930 for injection, Paclitaxel for injection (albumin-bound), TQB3616 capsule, Fulvestrant injection, Capecitabine tablets, Vinorelbine tartrate injection, Eribulin mesylate injection, gemcitabine hydrochloride for injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Metastatic Breast Cancer, Recurrent Breast Cancer, Advanced Malignancies | 12/26 | 10/27 | | |
SOLARA, NCT04711824: Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases |
|
|
| Recruiting | 1/2 | 41 | US | Olaparib, Lynparza, Stereotactic Radiosurgery, SRS, Durvalumab, Imfinzi, Physicians Choice systemic chemotherapy, Paclitaxel, Nab-paclitaxel, Eribulin, Carboplatin, Cisplatin, Capecitabine, Gemcitabine | Colette Shen, AstraZeneca, University of North Carolina, Chapel Hill | Breast Cancer, Brain Metastases, Adult | 05/24 | 09/26 | | |
NCT00365157: Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction |
|
|
| Active, not recruiting | 1/2 | 132 | US | Eribulin Mesylate, B1939 Mesylate, E7389, ER-086526 Mesylate, Halaven, Halichondrin B Analog, Laboratory Biomarker Analysis, Pharmacological Study | National Cancer Institute (NCI) | Advanced Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Urothelial Carcinoma, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage IV Bladder Urothelial Carcinoma AJCC v7, Unresectable Urothelial Carcinoma | 08/24 | 08/24 | | |
